HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jing Hu Selected Research

eriocalyxin B

8/2020Correction to: Eriocalyxin B Inhibits Adipogenesis in 3T3‑L1 Adipocytes by Cell Cycle Arrest.
6/2020Eriocalyxin B Inhibits Adipogenesis in 3T3-L1 Adipocytes by Cell Cycle Arrest.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jing Hu Research Topics

Disease

199Neoplasms (Cancer)
11/2022 - 03/2003
33Neoplasm Metastasis (Metastasis)
03/2022 - 10/2011
31Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2022 - 09/2002
29Inflammation (Inflammations)
01/2022 - 01/2008
23Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 04/2007
22Breast Neoplasms (Breast Cancer)
03/2022 - 04/2010
22Infections
02/2022 - 02/2004
19Carcinogenesis
01/2022 - 05/2004
18Fibrosis (Cirrhosis)
04/2022 - 10/2006
17Hepatocellular Carcinoma (Hepatoma)
10/2022 - 09/2015
17Lung Neoplasms (Lung Cancer)
01/2022 - 09/2002
14Pain (Aches)
10/2021 - 01/2008
13Prostatic Neoplasms (Prostate Cancer)
01/2022 - 04/2007
12Myocardial Infarction
02/2022 - 05/2009
11Bone Resorption
01/2022 - 02/2009
11Body Weight (Weight, Body)
10/2021 - 10/2009
11Carcinoma (Carcinomatosis)
07/2018 - 01/2006
10Stomach Neoplasms (Stomach Cancer)
02/2022 - 06/2013
10Adenocarcinoma of Lung
10/2021 - 01/2017
9Hypoxia (Hypoxemia)
12/2022 - 05/2008
9Osteoporosis
12/2020 - 08/2010
8Migraine Disorders (Migraine)
07/2022 - 08/2009
8Wounds and Injuries (Trauma)
05/2021 - 04/2004
8Infarction (Infarctions)
08/2020 - 01/2012
7Leukemia
06/2022 - 11/2011
7Nasopharyngeal Carcinoma
03/2022 - 01/2018
7Sepsis (Septicemia)
12/2021 - 08/2006
7Cognitive Dysfunction
05/2021 - 06/2016
7Type 2 Diabetes Mellitus (MODY)
01/2021 - 12/2008
7Pancreatitis
11/2020 - 11/2013
7Reperfusion Injury
01/2018 - 01/2014
7Ovarian Neoplasms (Ovarian Cancer)
08/2015 - 08/2010
6Ischemic Stroke
07/2022 - 09/2012
6Acquired Immunodeficiency Syndrome (AIDS)
06/2022 - 02/2016
6Rheumatoid Arthritis
03/2022 - 01/2016
6Autoimmune Diseases (Autoimmune Disease)
02/2022 - 02/2014
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 01/2016
6Thrombosis (Thrombus)
01/2022 - 05/2013
6Psoriasis (Pustulosis Palmaris et Plantaris)
07/2021 - 01/2018
6Ischemia
06/2021 - 02/2012
6Stroke (Strokes)
06/2021 - 06/2006
6Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2019 - 03/2016
6Abdominal Pain (Pain, Abdominal)
08/2018 - 06/2010
6Congenital Abnormalities (Deformity)
11/2016 - 12/2011
6Osteoarthritis
01/2015 - 07/2003
5Muscular Diseases (Myopathy)
08/2022 - 01/2002
5Heart Failure
04/2022 - 09/2012
5Necrosis
02/2022 - 01/2013
5Squamous Cell Carcinoma of Head and Neck
01/2022 - 05/2008

Drug/Important Bio-Agent (IBA)

79Proteins (Proteins, Gene)FDA Link
12/2022 - 01/2006
36Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2011
34Pharmaceutical PreparationsIBA
01/2022 - 07/2009
27Biological ProductsIBA
06/2022 - 03/2003
25MicroRNAs (MicroRNA)IBA
04/2022 - 04/2013
23Messenger RNA (mRNA)IBA
03/2022 - 01/2006
23Long Noncoding RNAIBA
02/2022 - 03/2016
20RNA (Ribonucleic Acid)IBA
01/2022 - 02/2004
16Therapeutic UsesIBA
01/2022 - 06/2006
14CateninsIBA
12/2022 - 03/2014
14ErbB Receptors (EGF Receptor)IBA
11/2021 - 06/2013
13CytokinesIBA
02/2022 - 06/2013
12Cisplatin (Platino)FDA LinkGeneric
01/2022 - 01/2006
12Transcription Factors (Transcription Factor)IBA
11/2021 - 04/2010
12Glucose (Dextrose)FDA LinkGeneric
06/2021 - 04/2013
11Interleukin-6 (Interleukin 6)IBA
02/2022 - 05/2015
11Phosphotransferases (Kinase)IBA
08/2021 - 09/2002
11DNA (Deoxyribonucleic Acid)IBA
01/2020 - 03/2003
10CalciumIBA
06/2021 - 06/2014
10Peptides (Polypeptides)IBA
01/2019 - 11/2011
9CollagenIBA
04/2022 - 04/2007
9Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 12/2015
9EnzymesIBA
01/2022 - 01/2012
8Indicators and Reagents (Reagents)IBA
03/2022 - 08/2010
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2022 - 07/2009
8Tyrosine Kinase InhibitorsIBA
01/2022 - 12/2015
7VaccinesIBA
11/2021 - 05/2015
7Estrogen ReceptorsIBA
01/2021 - 04/2010
7Small Interfering RNA (siRNA)IBA
01/2021 - 05/2007
7AntigensIBA
01/2021 - 02/2009
6Transforming Growth Factor beta (TGF-beta)IBA
04/2022 - 01/2009
6Antiviral Agents (Antivirals)IBA
01/2022 - 12/2017
6AndrogensIBA
01/2022 - 09/2015
6CholesterolIBA
12/2021 - 01/2012
6InterleukinsIBA
01/2021 - 10/2013
6AcidsIBA
01/2021 - 01/2008
6Monoclonal AntibodiesIBA
02/2019 - 04/2014
6Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
01/2019 - 08/2009
6Caspase 3 (Caspase-3)IBA
01/2017 - 11/2011
5Cadherins (E-Cadherin)IBA
12/2022 - 06/2014
5Analgesics (Analgesic Drugs)IBA
01/2022 - 06/2013
5Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 08/2015
5Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 08/2010

Therapy/Procedure

65Therapeutics
06/2022 - 03/2003
31Drug Therapy (Chemotherapy)
03/2022 - 03/2011
16Chinese Traditional Medicine (Traditional Chinese Medicine)
01/2022 - 05/2009
10Radiotherapy
06/2022 - 11/2012
9Immunotherapy
06/2022 - 01/2015
8Aftercare (After-Treatment)
03/2022 - 10/2010
7Osteotomy
02/2016 - 09/2007
6Moxibustion
01/2022 - 07/2016